

รายการอ้างอิง

1. Weinstein IB, Gattoni-Celli S, Kirxhmeier P. Multistage carcinogenesis involves multiple genes and multiple mechanisms. *J Cellular Physiol* 1984; Suppl 3: 127-37.
2. Marshall CJ. Oncogenes and cell proliferation. In : Glover DM, Hames BD, editors. *Oncogenes*. Oxford : Bios Scientific, 1989: 1-21.
3. Macdonal F, Ford C. Tumor Suppressor Genes. In : Macdonal F, Ford C, editors. *Oncogenes and tumor suppressor genes*. Oxford : Bios Scientific, 1991: 19-35.
4. Harris C, Hallstein M. Clinical implication of the *p53* tumor suppressor gene. *N Eng J Med* 1993; 329: 1318-27.
5. Knudson A, Meadow A, Nichols W, Hill R. Chromosomal deletion and retinoblastoma. *N Eng J Med* 1976; 295: 1120-3.
6. Benedict W, Murphree A, Banerjee A, Spina C, Sparkes M, Sparkers R. Patient with 13 chromosome deletion : evidence that the retinoblastoma gene is a recessive cellular gene. *Science* 1983; 219: 973-5.
7. Trent RJ. Medical oncology. In : Trent RJ, editor. *Molecular medicine*. Churchill Livingstone, 1993: 121-49.
8. Kinzler KW, Nilbert MC, Su LK. Identification of *FAP* locus genes from chromosome 5q21. *Science* 1991; 253: 661-5.
9. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. *Cancer* 1993; 71: 677-85.
10. Fearson ER, Cho KR, Nigro JM. Identification of a chromosome 18q genes that is altered in colorectal cancers. *Science* 1990; 247: 49-56.
11. Malkin D, Li F, Strong L. Germ line *p53* mutation in a familial syndrome of breast cancer, sarcomas and other neoplasms. *Science* 1990; 250: 1223.
12. Coppes MJ, Huff V, Pellertier J. Denys - Drash syndrome relating a clinical disorder to genetic alterations in the tumor suppressor gene *WT1*. *J Pediatr* 1993; 123: 673-8.

13. Bunin GR, Emanuel BS, Meadows AT, Buckley JD, Woods WG, Hammond GD.
Frequency of 13q abnormalities among 203 patients with retinoblastoma.
J Natl Cancer Inst 1989; 81: 370-6.
14. Pisharodi LR, Lavoie R, Bedrossian CW. Differential diagnostic dilemmas in malignant fine-needle aspirates of liver : a practical approach to final diagnosis.
Diagnostic Cytopathology 1995; 12(4): 364-70.
15. Fucich L, Cheles M, Thung S, Gerber M, Marrogi A. Primary vs metastatic hepatic carcinoma, an immunohistochemical study of 34 cases. *Arch Patho Lab Med* 1994; 118: 927-30.
16. Steiner G, Sidransky D. Commentary . Molecular differential diagnosis of renal carcinoma from microscopes to microsattelites. *American J of Clin Patho* 1996; 149(6): 1791-5.
17. Boige V, Laurent-Puig P, Fouchet P, Flejou JF, Monges G, Bedossa P, et al. Concerted nonsynthetic alleic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution alleotype. *Cancer Research* 1997; 57(10): 1986-90.
18. Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC, Chen DS. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. *Cancer Research* 1994; 54 (15): 4188-92.
19. Kuroki T, Fujiwara Y, Tsuchiya E, Nakamori S, Imaoka S, Kanematsu T, et al.
Accumulation of genetic changes during development and progression of hepatocellular carcinoma : loss of heterozygosity of chromosome arm 1p occurs at and early stage of hepatocarcinogenesis. *Genes, Chromosome & Cancer* 1995; 13(3): 163-7.
20. Vogelstein B, Fearson E, Kerin S, Hamilton S, Preisinger A, Nakamura Y. Alleotype of colorectal carcinomas. *Science* 1989; 244: 207-11.
21. Piao Z, Kim H, Jeon BK, Lee WJ, Park C. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. *Cancer* 1997; 80(5): 865-72.

22. Leon M, Kew MC. Loss of heterozygosity in chromosome 4q12-q13 in hepatocellular carcinoma in southern African blacks. *Anticancer Research* 1996; 16(1): 349-51.
23. Yumoto Y, Hanafusa T, Hada H, Morita T, Ooguchi S, Shinji N, et al. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. *Journal of Gastroenterology & Hepatology* 1995; 10(2): 179-85.
24. Fujimoto Y. Aberrations of tumor suppressor genes in hepatocellular carcinomas. *Hokkaido Journal of Medical Science* 1994; 69(5): 1252-60.
25. Iacopetta B, Di Grandi S, Dix B, Haig C, Soong R, House A. Loss of heterozygosity of tumor suppressor gene loci in human colorectal carcinoma. *European Journal of Cancer* 1994; 30(5): 664-70.
26. Miki Y, Nishisho I, Miyochi Y, Nakamura Y. Cytomolecular aspects of colorectal carcinoma. *Ganto Kagaku Ryoho* 1991; 18(4): 515-21.
27. Sasaki M, Okamoto M, Sato C, Sugio K, Soejima J, Iwama T, et al. Loss of constitutional heterozygosity in colorectal tumors from patients with familial polyposis coli and those with nonpolyposis colorectal carcinoma. *Cancer Research* 1989; 49(16): 4402-6.
28. De Souza AT, Hankins GR, Washington MK, Ortan TC, Jirtle RL. *M6P/IGF2R* gene is mutated in hepatocellular carcinomas with loss of heterozygosity. *Nature Genetic* 1995; 11(4): 447-9.
29. Takahashi K, Kudo J, Ishibashi H, Hirata Y, Niho Y. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma. *Hepatology* 1993; 17(5): 794-9.
30. Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi H, Koike M, et al. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. *Genes, Chromosome & Cancer* 1993; 7(3):152-7.
31. Naga H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive alleotyping of human hepatocellular carcinoma. *Oncogene* 1997; 14(24): 2927-33.
32. Becker SA, Zhou YZ, Slagle BL. Frequent loss of chromosome 8p in hepatitis B virus-positive hepatocellular carcinomas from china. *Cancer Research* 1996; 56(21): 5092-7.

33. Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, et al. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. *Journal of Cancer Research & Clinical Oncology* 1996; 122(10): 585-9.
34. Cunningham C, Dunlop MG, Bird CC, Wyllie AH. Deletion analysis of chromosome 8p in sporadic colorectal adenomas. *British Journal of Cancer* 1994; 70(1): 18-20.
35. Keldysh PL, Dragani TA, Fleischman EW, Konstantinova LN, Perevoschikov AG, Pierotti MA, et al. 11q deletions in human colorectal carcinomas : cytogenetic and restriction fragment length polymorphism analysis. *Genes, Chromosome & Cancer* 1993; 6(1): 45-50.
36. Ookawa K, Sakamoto M, Hirohashi S, Yoshida Y, Sugimura T, Terada M, et al. Concordant p53 and DCC alterations and allelic losses on chromosome 13q and 14q associated with liver metastases of colorectal carcinoma. *International Journal of Cancer* 1993; 53(3): 382-7.
37. Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S, et al. Deletions of chromosome 13q mutations in Retinoblastoma, and retinoblastoma protein state in human hepatocellular carcinoma. *Cancer Research* 1994; 54(15): 4177-82.
38. Young J, Leggett B, Ward M, Thomas L, Buttenshaw R, Searle J, et al. Frequent loss of heterozygosity on chromosome 14 occurs in advanced colorectal carcinomas. *Oncogene* 1993; 8(3): 671-5.
39. Nishida N, Fukuda Y, Kokuruya H, Toguchida J, Yandell DW, Ikenega M, et al. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. *Cancer Research* 1993; 53(2): 368-72.
40. Takahashi K, Kudo J, Ishibashi H, Hirata Y, Niho Y. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma. *Hepatology* 1993; 17(5): 794-9.
41. Bertorelle R, Esposito G, Del Mistro A, Belluco C, Nitti D, Lise M, et al. Association of p53 gene and protein alterations with metastases in colorectal cancer. *American Journal of Surgical Pathology* 1995; 19(4): 463-71.

42. Okada K, Urano T, Goi T, Baba H, Yamaguchi A, Furukawa K, et al. Isolation of human nm23 genomes and analysis of loss of heterozygosity in primary colorectal carcinomas using a specific genomic probe. *Cancer Research* 1994; 54(15): 3979-82.
43. Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, et al. Prognostic significance of the loss of heterozygosity of *Nm23-H1* and *p53* genes in human colorectal carcinomas. *Cancer* 1994; 73 (12) 2913-21.
44. Ayhan A, Yasui W, Yokozaki H, Seto M, Ueda R, Tahara E. Loss of heterozygosity at the *bcl-2* gene locus and expression of *bcl-2* in human gastric and colorectal carcinomas. *Japanese Journal of Cancer Research* 1994; 85(6): 584-91.
45. Ding F-S, Delhanty JDA, Zografos, Michail NE, Dooley JS. Chromosome allele loss in colorectal liver metastasis and its association with clinical features. *British Journal of Surg* 1994; 81: 875-8.
46. Kana Y, Ushijima S, Tsuda H, Sakamoto M, Sugimura T, Hirohashi S. Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. *Japanese Journal of Cancer Research* 1996; 87(12): 1210-7.
47. Kato M, Ito Y, Kabayashi S, Isono K. Detection of DCC and Ki-ras Gene Alterations in Colorectal Carcinoma Tissue as Prognostic Markers for Liver Metastatic Recurrence. *Cancer* 1996; 77: 1729-35.
48. Reagan J, Hamonic M. The cellular pathology in carcinoma in situ: a cytohistopathological correlation. *Cancer* 1956; 9: 385-92.
49. Dupont W, Page D. Risk factors for breast cancer in women with proliferative breast disease. *N Eng J Med* 1985; 312: 146-51.
50. O' Brien M, Winawer S, Zauber A, Gottlieb L, Sterberg S, Diaz B, et al. The National Polyp Study Workgroup. The National Polyp Study patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. *Gastroenterology* 1990; 98: 371-88.
51. Harris C. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. *Carcinogenesis* 1989; 10: 1563-3.

52. Poirier M, Beland F. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models : implications for DNA adduct-based human cancer risk assessment. *Chem Res Toxicol* 1992; 5: 749-56.
53. Cairn J. Mutation selection and the natural history of cancer. *Nature* 1975; 255: 197-23.
54. Diamond L. Tumor promoters and cell transformation. *Pharmacol Ther* 1984; 26: 189-45.
55. Berenblum I, Shubik P. A new quantitative approach to the study of the stages of chemical carcinogenesis in the mouse skin. *Br J Cancer* 1947; 1: 383-96.
56. Loeb L, Cheng K. Errors in DNA synthesis : a source of spontaneous mutations. *Mutat Res* 1990; 238: 297-301.
57. Yuspa S, Poirier M. Chemical carcinogenesis : from animal models to molecular models in one decade. *Adv Cancer Res* 1988; 50: 25-34.
58. Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. *Biochem Biophys Acta* 1989; 989: 65.
59. Peltomaki P, Altonen L, Sistonen P, Pylkkanen L, Mecklin J, Jarvinen H, et al. Genetic mapping of a locus predisposing to human colorectal cancer. *Science* 1993; 260: 810-2.
60. Barbacid M. ras Genes. *Ann Rev Biochem* 1987; 56:779-827.
61. Rabbitts T. Chromosomal translocation in human cancer. *Nature* 1994; 372: 143.
62. U HS, Kelly P, Hatton J, Shew J. Proto-oncogene abnormalities and their relationship to tumorigenicity in some human glioblastomas. *J Neurosurg* 1989; 71: 83-9.
63. Clark G, Sledge G Jr, Osborne C, McGuire W. Survival from first recurrence : relative importance of prognostic factors in 1,015 breast cancer patients. *J Clin Oncol* 1987; 5: 55-61.
64. Little C, Nau M, Carney D. Amplification and expression of the c-Myc oncogene in human lung cancer cell lines. *Nature* 1983; 306:194.
65. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. *Nature* 1969; 223: 363-8.
66. Harris H. The analysis of malignancy by cell fusion : the position in 1988. *Cancer Research* 1988; 48:3302-6.
67. Knudson A. Mutation and cancer : statistical study of retinoblastoma. *Proc Natl Acad Sci USA* 1971; 68:820-3.

68. Cavenee W, Dryja T, Phillips R, Benedict W, Godbout R, Gallie B, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature* 1983; 305: 779-84.
69. Bishop J. Molecular themes in oncogenesis. *Cell* 1991; 64: 235-44.
70. Michael R. Mechanisms of activation and inactivation of dominant oncogenes and tumour suppressor gene. In : J.R Yarnold, M.R Stratton, T.J McMillan, editors. *Molecular biology for oncologists*. Chapman Hall, 1996; 16-26.
71. Cavenee W, Dryja T, Phillips R, Benedict W, Godbout R, Gallie B, et al. Expression of recessive alleles by chromosomal mechanism in retinoblastoma. *Cell* 1983; 305: 779-84.
72. Sager R. Tumour suppressor genes : the puzzle and the promise. *Science* 1989; 246: 1406-12.
73. Weinberg R. Tumor suppressor genes. *Science* 1991; 254: 1138-46.
74. Mulligan L, Mole S. Strategies for isolating genes in hereditary and sporadic tumours. In : Levine AJ, Schmidek HH, editors. *Molecular genetics of nervous system tumours*. New York : Wiley-Liss, 1993: 195-208.
75. Louis D, Deimling A, Seinyinger B. A (CA)_n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in archival human brain tumour specimens. *Am J Patho* 1992; 141: 777-82.
76. Huang T, Quesenberry J, Martin M, Loy T, Diaz-Arias A. Loss of heterozygosity detected in formalin-fixed, paraffin-embedded tissue of colorectal carcinoma using a microsatellite located within the deleted in colorectal carcinoma gene. *Diagnos Molec Patho* 1993; 2: 90-3.
77. Weber J. Informativeness of human (dC-dA)_n. (dG-dT)_n polymorphisms. *Genomics* 1990; 7: 524-30.
78. Litt M, Luty J. A hypervariable microsatellite revealed by in vitro amplification of a dinucleotide repeat within the cardiac muscle actin gene. *Am J Hum Genet* 1989; 44: 397-401.

ภาคผนวก

สารละลายและบัฟเฟอร์ที่ใช้

1. 1M Tris (pH 7.0)

Tris base	121.1	g
dH ₂ O	700	ml

* ปรับให้มี pH 7.0 โดยการเติม HCl

* ผสมน้ำปรับให้ครบปริมาตร 1 ลิตรและทำให้ปราศจากเชื้อโดยวิธีการ autoclave

2. 0.5 M EDTA (pH 8.0)

Disodium ethylenediamine tetraacetate. 2H ₂ O	186.6	g
dH ₂ O	700	ml

* ปรับให้มี pH 8.0 โดยการเติม NaOH

* ผสมน้ำปรับให้ครบปริมาตร 1 ลิตรและทำให้ปราศจากเชื้อโดยวิธีการ autoclave

3. 10M Ammonium acetate (CH₃COONH₄)

Ammonium acetate	770	g
dH ₂ O	700	ml

* ผสมน้ำปรับให้ครบปริมาตร 1 ลิตรและทำให้ปราศจากเชื้อโดยวิธีการกรอง

4. 10X TBE buffer

Tris base	104	g
Boric acid	55	g
0.5 M EDTA	40	ml

* ผสมน้ำปรับให้ครบปริมาตร 1 ลิตรและกรองผ่านกระดาษกรอง Whatman เบอร์ 1

5. 6M NaCl

NaCl	350.64	g
dH ₂ O	600	ml

* ผสมน้ำปรับให้ครบปริมาตร 1 ลิตรและทำให้ปราศจากเชื้อโดยวิธีการ autoclave

6. 25% Ammonium Persulfate : (NH₄)₂S₂O₈

Ammonium Persulfate	2.5	g
ผสมน้ำให้มีปริมาตร	4	ml

* เก็บในอุณหภูมิ 4 องศาเซลเซียส

7. Proteinase K (Stock solution)

Dissolve Proteinase K	20	mg
dH ₂ O	1	ml

* เก็บในอุณหภูมิ -20 องศาเซลเซียส

8. 10% Sodium dodecyl sulfate (SDS)

SDS (electrophoretic grade)	100	g
dH ₂ O	870	ml

* ปรับให้มี pH 7.2 โดยการเติม Hcl

* ผสมน้ำปรับให้ครบปริมาตร 1 ลิตร

9. Digestion buffer

100 mM NaCl
10 mM Tris Hcl (pH 8.0)
25 mM EDTA (pH 8.0)
0.5% SDS
0.1 mg/ml PK

10. T₁₀E₁₀

1M Tris	1	ml
0.5 M EDTA	2	ml
dH ₂ O	97	ml

11. T₁₀E₁

1 M Tris	1	ml
0.5 M EDTA	0.2	ml
dH ₂ O	100	ml

12. Loading dye

0.025% Xylene cyanol FF	2.5	mg
0.025% Bromophenol blue in dH ₂ O	2.5	mg
98% Deionized formamide	9.8	ml
10 mM EDTA	0.2	ml

ประวัติผู้เขียน

นางสาวเอื้อมแซ สุขประเสริฐ เกิดวันที่ 12 กันยายน พ.ศ. 2509 ที่จังหวัดกรุงเทพมหานคร สำเร็จการศึกษาปริญญาตรีแพทยศาสตรบัณฑิต เกียรตินิยมอันดับสอง จากคณะแพทยศาสตร์มหาวิทยาลัยขอนแก่น และศึกษาต่อเป็นแพทย์เฉพาะทางสาขาอายุรศาสตร์ ที่ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น สำเร็จการศึกษาในปีพ.ศ. 2536 จากนั้นรับราชการในตำแหน่งอาจารย์ประจำหน่วยโลหิตวิทยา ภาควิชาอายุรศาสตร์ มหาวิทยาลัยขอนแก่น และเข้าศึกษาต่อระดับผู้เชี่ยวชาญเฉพาะสาขาย่อย มะเร็งวิทยา ที่ภาควิชาอายุรศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย และศึกษาในหลักสูตรวิทยาศาสตรมหาบัณฑิต ที่จุฬาลงกรณ์มหาวิทยาลัย เมื่อพ.ศ. 2540 ปัจจุบันรับราชการในตำแหน่งอาจารย์ประจำหน่วยมะเร็งวิทยา ภาควิชาอายุรศาสตร์ มหาวิทยาลัยขอนแก่น

